Silver Book Fact

The use of antioxidant vitamins and other new therapies for age-related macular degeneration (AMD) could reduce visual impairment and blindness from the disease by 35%.

Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group. Forecasting Age-Related Macular Degeneration Through the Year 2050. JAMA Ophthalmol. 2009; 127(4): 533-40. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/422785

Reference

Title
Forecasting Age-Related Macular Degeneration Through the Year 2050
Publication
JAMA Ophthalmol
Publication Date
2009
Authors
Rein, David. B., John S. Wittenborn, Xinzhi Zhang, Amanda A. Honeycutt, Sarah B. Lessene, and Jinan Saadine; for the Vision Health Cost-Effectiveness Study Group
Volume & Issue
Volume 127, Issue 4
Pages
533-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • The NEI-sponsored Ocular Hypertensive Treatment Study (OHTS) found that lowering intraocular pressure (IOP) by at least 20% produced a 50% protective benefit for individuals who had an elevated IOP but…  
  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • A study on the impact of diet on age-related macular degeneration (AMD) found that those who took the highest amounts of carotenoids, such as lutein and zeaxanthin, had a 43%…  
  • Nearly 50% of diabetic retinopathy patients who received ranibizumab–an anti-VEGF drug–experienced substantial visual improvement after a year of injections  
  • High-intensity ultrasonic cyclocoagulation reduces intraocular pressure in refractory glaucoma patients.